QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)

Sutro Biopharma Stock Price, News & Analysis (NASDAQ:STRO)

$2.87
+0.12 (+4.36%)
(As of 12/4/2023 ET)
Compare
Today's Range
$2.69
$2.88
50-Day Range
$2.07
$3.98
52-Week Range
$2.01
$8.72
Volume
567,596 shs
Average Volume
522,511 shs
Market Capitalization
$174.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

Sutro Biopharma MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
387.8% Upside
$14.00 Price Target
Short Interest
Healthy
3.77% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.97mentions of Sutro Biopharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.03) to ($3.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

68th out of 952 stocks

Biological Products, Except Diagnostic Industry

10th out of 155 stocks


STRO stock logo

About Sutro Biopharma Stock (NASDAQ:STRO)

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

STRO Stock Price History

STRO Stock News Headlines

AbbVie-ImmunoGen buyout deal lifts ADC-focused biotechs
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Expert Ratings for Sutro Biopharma
Sutro Biopharma Inc STRO
Oppenheimer Reaffirms Their Buy Rating on Sutro Biopharma (STRO)
5 Analysts Have This to Say About Sutro Biopharma
Sutro Biopharma Inc.
See More Headlines
Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STRO
Fax
N/A
Employees
298
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$25.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+387.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-119,200,000.00
Net Margins
-354.53%
Pretax Margin
-349.63%

Debt

Sales & Book Value

Annual Sales
$67.77 million
Book Value
$3.78 per share

Miscellaneous

Free Float
56,747,000
Market Cap
$174.93 million
Optionable
Not Optionable
Beta
0.86
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. William J. Newell J.D. (Age 65)
    CEO & Director
    Comp: $1.07M
  • Ms. Jane Chung R.Ph. (Age 52)
    Chief Commercial Officer
    Comp: $934.64k
  • Dr. James R. Swartz Ph.D.
    Sc.D., Founder
  • Mr. Edward C. Albini (Age 65)
    CFO & Secretary
    Comp: $596.4k
  • Dr. Venkatesh Srinivasan Ph.d.
    Chief Technical Operations Officer
  • Dr. Hans-Peter Gerber Ph.D.
    Chief Scientific Officer
  • Mr. David Pauling J.D.
    M.A., General Counsel
  • Ms. Linda A. Fitzpatrick (Age 66)
    Chief People & Communications Officer
    Comp: $595.79k
  • Dr. Nicki Vasquez Ph.D. (Age 60)
    Chief Portfolio Strategy & Alliance Officer
  • Ms. Brunilda Shtylla M.B.A. (Age 49)
    M.S., Chief Business Officer














STRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Sutro Biopharma stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STRO shares.
View STRO analyst ratings
or view top-rated stocks.

What is Sutro Biopharma's stock price target for 2024?

8 brokers have issued 1-year price objectives for Sutro Biopharma's stock. Their STRO share price targets range from $8.00 to $25.00. On average, they anticipate the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 387.8% from the stock's current price.
View analysts price targets for STRO
or view top-rated stocks among Wall Street analysts.

How have STRO shares performed in 2023?

Sutro Biopharma's stock was trading at $8.08 on January 1st, 2023. Since then, STRO shares have decreased by 64.5% and is now trading at $2.87.
View the best growth stocks for 2023 here
.

When is Sutro Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our STRO earnings forecast
.

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) announced its earnings results on Monday, November, 13th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by $0.05. Sutro Biopharma had a negative net margin of 354.53% and a negative trailing twelve-month return on equity of 99.73%.

What ETF holds Sutro Biopharma's stock ?

Simplify Propel Opportunities ETF holds 120,000 shares of STRO stock, representing 0.53% of its portfolio.

What is William J. Newell's approval rating as Sutro Biopharma's CEO?

11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV).

When did Sutro Biopharma IPO?

(STRO) raised $75 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Sutro Biopharma's major shareholders?

Sutro Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Rubric Capital Management LP (5.53%), Adage Capital Partners GP L.L.C. (5.13%), Kynam Capital Management LP (2.57%), Acadian Asset Management LLC (1.28%), Vontobel Holding Ltd. (0.74%) and Sectoral Asset Management Inc. (0.71%). Insiders that own company stock include Brunilda Shtylla, Nicki Vasquez, Trevor Hallam and William J Newell.
View institutional ownership trends
.

How do I buy shares of Sutro Biopharma?

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:STRO) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -